AHA 2014:CABG联合瓣膜修复对中度缺血性二尖瓣反流患者无益

2014-11-21 高晓方 译 医学论坛网

AHA科学年会的一项报告表明,在伴有中度缺血性二尖瓣反流的患者中,于冠脉旁路移植术(CABG)基础上联合实施瓣膜修补未产生任何临床获益,并且具有神经病学副作用。研究同时发表于《新英格兰医学杂志》(简称NEJM)。 此项研究共纳入301例伴有中度缺血性二尖瓣反流的多血管冠脉疾病患者,并随机给予CABG联合二尖瓣修补术或单纯CABG。主要终点为左室收缩期末容积指数(LVESVI),次要终点为

AHA科学年会的一项报告表明,在伴有中度缺血性二尖瓣反流的患者中,于冠脉旁路移植术(CABG)基础上联合实施瓣膜修补未产生任何临床获益,并且具有神经病学副作用。研究同时发表于《新英格兰医学杂志》(简称NEJM)。

此项研究共纳入301例伴有中度缺血性二尖瓣反流的多血管冠脉疾病患者,并随机给予CABG联合二尖瓣修补术或单纯CABG。主要终点为左室收缩期末容积指数(LVESVI),次要终点为严重不良心脏或脑血管事件。

结果显示,1年时两组患者的主要终点和次要终点均无显著差异,但联合治疗组的神经病学事件(3.1%对9.6%,P=0.03)和室上性心律失常(8.4%对17.8%,P=0.03)发病率显著高于单纯治疗组。此外,联合二尖瓣修补与旁路时间延长57分钟、术后住院时间延长和房颤发病率升高具有相关性。

研究者之一Timothy Gardner博士表示,他们也不确定联合瓣膜修补术值不值得做。似乎有些类似该研究中的患者进行二尖瓣修复也合适,但他们还没有将这部分患者分类出来,还需要进行亚组分析。另外,目前为止只进行了1年的随访,因此应审慎对待该研究结果,未来还需为期更长的随访,以进一步探索那些未知。

美国麻省总医院Sundt博士评论说,活动性可逆性缺血和心梗均可造成缺血性二尖瓣反流。由可逆性缺血造成的心室功能障碍可通过单纯血运重建纠正,心梗为病史时则可能无法通过上述方法缓解。该研究同时纳入了两种类型的患者,因此结果可能受到相关混淆因素的影响。

原始出处:

No Advantage Seen to Surgical Repair Added to CABG for Ischemic Mitral Regurgitation

         

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892630, encodeId=0466189263054, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jun 28 01:51:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267239, encodeId=de00126e239c9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463138, encodeId=157514631386e, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571558, encodeId=4b6c15e1558ac, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583443, encodeId=7f3715834433f, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892630, encodeId=0466189263054, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jun 28 01:51:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267239, encodeId=de00126e239c9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463138, encodeId=157514631386e, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571558, encodeId=4b6c15e1558ac, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583443, encodeId=7f3715834433f, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892630, encodeId=0466189263054, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jun 28 01:51:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267239, encodeId=de00126e239c9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463138, encodeId=157514631386e, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571558, encodeId=4b6c15e1558ac, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583443, encodeId=7f3715834433f, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 wwzzly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892630, encodeId=0466189263054, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jun 28 01:51:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267239, encodeId=de00126e239c9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463138, encodeId=157514631386e, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571558, encodeId=4b6c15e1558ac, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583443, encodeId=7f3715834433f, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 feifers
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892630, encodeId=0466189263054, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jun 28 01:51:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267239, encodeId=de00126e239c9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463138, encodeId=157514631386e, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571558, encodeId=4b6c15e1558ac, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583443, encodeId=7f3715834433f, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Nov 23 00:51:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]

相关资讯

CHC 2013:冠心病CABG治疗的克利夫兰经验

近日,在2013中国心脏大会(CHC2013)第二届心血管国际研讨会上,美国克利夫兰医学中心Ed Soltesz教授作了题为“冠状动脉再血管化治疗方法的现状”的演讲。据Ed Soltesz教授介绍,美国克利夫兰医学中心每年高龄、复杂、多合并症病例比例明显升高,冠心病冠状动脉旁路移植手术(CABG)治疗策略有了很多改变。 Ed Soltesz 从CABG的几种手术方法的对比(包

胡大一:认真学习贯彻指南

作者:胡大一(北京大学人民医院心研所所长、卫生部健康教育首席专家) 近年来,国内外各种疾病诊疗指南引起政府、医生和公众的广泛重视。这本是件好事,但如果只是走马观花式学习指南,不认真坐下来阅读,就难以理解指南要义;更重要的是,在贯彻指南时,不能有意歪曲指南的推荐,掺入商业利益,为药物、器械或影像技术的不恰当使用、过度使用甚至滥用摇旗呐喊。 举个例子。2013年9月在欧洲心脏病学学会的年会上公布了

Eur Heart J:CABG仍为冠脉三支病变标准治疗方案

欧美一项研究表明,在三支血管病变(3VD)患者中,冠脉旁路移植(CABG)的死亡、心肌梗死和重复血运重建发生率均低于第一代紫杉醇洗脱支架经皮冠脉介入(PCI)治疗,故仍应作为标准治疗方案。论文5月21日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入1095例新发3VD或左主干病变患者,并随机给予第一代紫杉醇洗脱支架PCI或CABG治疗。随访5年后评估严重不良心脏和脑血管事

JAMA Intern Med:多支血管病变患者CABG还是PCI?

土耳其一项荟萃分析表明,在多支血管冠脉疾病患者中,无论其合并糖尿病与否,与经皮冠脉介入(PCI)相比,冠脉旁路移植(CABG)可显著降低远期死亡率以及心梗和重复血运重建率。论文12月2日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。 研究者检索了相关数据库,并纳入了直接比较CABG与PCI的随机对照试验。在报告转归的多支血管病变患者中,至少需

Ann Intern Med:CABG联合药物治疗可改善冠脉多支病变患者生活质量

美国一项研究表明,在缺血性左室功能障碍和多支冠脉疾病患者中,与单纯药物治疗相比,冠脉旁路移植术(CABG)联合药物治疗可显著改善生活质量。论文9月16日在线发表于《内科学年鉴》(Ann Intern Med )。 此项研究共纳入1212例左室射血分数≤35%的冠脉疾病患者,并随机给予单纯药物治疗或药物治疗联合CABG。在基线和随机化后4、12、24和36个月时,通过堪萨斯城心肌病调查问卷

JAMA Intern Med:多支血管病变者CABG更优?

土耳其一项荟萃分析表明,在多支血管冠脉疾病患者中,无论其合并糖尿病与否,与经皮冠脉介入(PCI)相比,冠脉旁路移植(CABG)可显著降低远期死亡率以及心梗和重复血运重建率。论文12月2日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。 研究者检索了相关数据库,并纳入了直接比较CABG与PCI的随机对照试验。在报告转归的多支血管病变患者中,至少需有90%应用1支及以